Spero therapeutics announces the initiation of bronchoalveolar lavage and renal impairment clinical trials of spr206

Cambridge, mass., june 15, 2021 (globe newswire) -- spero therapeutics, inc. (nasdaq: spro), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the initiation of two phase 1 trials of spr206, an intravenously (iv)-administered next-generation polymyxin product candidate. spr206 was derived from spero's potentiator platform and is being developed to treat serious multi-drug resistant (mdr) gram-negative infections in the hospital setting. these trials, which are now open for enrollment, include a bronchoalveolar lavage (bal) clinical trial assessing the penetration of spr206 into the pulmonary compartment and a renal impairment clinical trial.
SPRO Ratings Summary
SPRO Quant Ranking